Use of suramin in treatment of prostatic carcinoma refractory to conventional hormonal manipulation

This observation, together with the drug's documented growth inhibitory effect on prostate cells in vitro and its adrenocorticolytic properties in vivo, provides the rationale for evaluationg the therapeutic efficacy of suramin in patients with prostate cancer refractory to conventional hormonal therapy